⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 4, 2026British Journal of Haematology

Post‐dose observation after subcutaneous daratumumab: A service evaluation of safety and capacity impact

Faye Sharpley Hannah Miller J. Pealing Catherine Loughran

View at Publisher

Ask AI

Bookmark

Share

Key Points

Evaluate the safety and capacity impact of post-dose observation following subcutaneous daratumumab administration.
Service evaluation was conducted after subcutaneous daratumumab administration.
Data were collected on safety outcomes and capacity metrics relevant to post-dose observation.
Findings were made available upon reasonable request.
Findings indicate potential safety issues associated with daratumumab administration.
Capacity impact demonstrates significant resource utilization following the treatment.

Implication

Service evaluation investigates safety and capacity impact of subcutaneous daratumumab administration.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sharpley et al. (2026) studied this question.

synapsesocial.com/papers/6a23ba3c71a5da9775e75fcd https://doi.org/10.1111/bjh.70604

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Administration-related reactions following first-dose subcutaneous daratumumab to inform implementation of a 30-minute observation periodCohort Study · 2026
2Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010)2024 · 4 citations
3An Open-Label, Pilot Study of Daratumumab SC in Mild to Moderate Alzheimer’s Disease2024 · 5 citations
4Real-world analysis of infusion-related reactions in patients receiving subcutaneous daratumumab in Nova Scotia, CanadaObservational Study · 2026
5Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaEarly-Phase Clinical Trial · 2019 · 116 citations

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma2018
Real-world outcomes of daratumumab in light-chain amyloidosis patients with advanced renal failure: A TriNetX network study.2026
Open-label, single-arm study to assess the implementation of and patient experience with home-based daratumumab administration in patients being treated for multiple myeloma2025
Ageing and female sex progressively remodel B‐ and T‐cell compartments to strain peripheral T‐cell tolerance to red blood cell autoantigensBritish Journal of Haematology · 2026
Second allogeneic haematopoietic stem cell transplantation for non‐malignant diseasesBritish Journal of Haematology · 2026

More from British Journal of Haematology

More from The Christie NHS Foundation Trust

More from University Hospitals of Leicester NHS Trust